MX2021000611A - Una sal de xinafoato de un compuesto inhibidor de jak. - Google Patents

Una sal de xinafoato de un compuesto inhibidor de jak.

Info

Publication number
MX2021000611A
MX2021000611A MX2021000611A MX2021000611A MX2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A
Authority
MX
Mexico
Prior art keywords
inhibiting compound
xinafoate salt
formula
jak
jak inhibiting
Prior art date
Application number
MX2021000611A
Other languages
English (en)
Spanish (es)
Inventor
James Mccabe
Anna Matilda Angelica Pettersen
Carl - Johan AURELL
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021000611A publication Critical patent/MX2021000611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021000611A 2018-07-18 2019-07-17 Una sal de xinafoato de un compuesto inhibidor de jak. MX2021000611A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699955P 2018-07-18 2018-07-18
US201962866013P 2019-06-25 2019-06-25
PCT/EP2019/069252 WO2020016302A1 (en) 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound

Publications (1)

Publication Number Publication Date
MX2021000611A true MX2021000611A (es) 2021-04-13

Family

ID=67396927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000611A MX2021000611A (es) 2018-07-18 2019-07-17 Una sal de xinafoato de un compuesto inhibidor de jak.

Country Status (14)

Country Link
US (1) US11149029B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823964A1 (cg-RX-API-DMAC7.html)
JP (2) JP7422732B2 (cg-RX-API-DMAC7.html)
KR (1) KR102849420B1 (cg-RX-API-DMAC7.html)
CN (2) CN112424187B (cg-RX-API-DMAC7.html)
AU (1) AU2019304014B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000467A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105585A1 (cg-RX-API-DMAC7.html)
IL (1) IL280025B2 (cg-RX-API-DMAC7.html)
MA (1) MA53162A (cg-RX-API-DMAC7.html)
MX (1) MX2021000611A (cg-RX-API-DMAC7.html)
MY (1) MY209356A (cg-RX-API-DMAC7.html)
SG (1) SG11202100240RA (cg-RX-API-DMAC7.html)
WO (1) WO2020016302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
GB202316063D0 (en) 2023-10-20 2023-12-06 Astrazeneca Ab Dosing regime
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor
WO2026132265A1 (en) 2024-12-19 2026-06-25 Astrazeneca Ab Dry powder inhaler

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2452965T3 (es) * 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
RU2013114352A (ru) * 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
DK3063143T3 (en) * 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
PL3189045T3 (pl) * 2014-08-11 2022-04-04 Sun Pharmaceutical Industries Limited Nowe sole nilotynibu i jego polimorfy
KR102774784B1 (ko) * 2015-09-25 2025-02-27 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak를 억제하기 위한 화합물 및 방법
PE20191108A1 (es) * 2017-01-17 2019-08-26 Astrazeneca Ab Inhibidores selectivos de jak1
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法

Also Published As

Publication number Publication date
IL280025A (en) 2021-03-01
WO2020016302A1 (en) 2020-01-23
AU2019304014B2 (en) 2022-08-18
JP2024001109A (ja) 2024-01-09
KR20210033474A (ko) 2021-03-26
IL280025B1 (en) 2024-10-01
AU2019304014A1 (en) 2021-03-04
EP3823964A1 (en) 2021-05-26
JP7422732B2 (ja) 2024-01-26
JP2021530526A (ja) 2021-11-11
CA3105585A1 (en) 2020-01-23
CN112424187B (zh) 2024-06-21
CN112424187A (zh) 2021-02-26
MA53162A (fr) 2021-05-26
CN118580223A (zh) 2024-09-03
JP7644190B2 (ja) 2025-03-11
US11149029B2 (en) 2021-10-19
WO2020016302A8 (en) 2020-11-12
US20200062737A1 (en) 2020-02-27
KR102849420B1 (ko) 2025-08-25
MY209356A (en) 2025-07-03
BR112021000467A2 (pt) 2021-04-06
SG11202100240RA (en) 2021-02-25
IL280025B2 (en) 2025-02-01

Similar Documents

Publication Publication Date Title
MX2023001876A (es) Derivados de rapamicina.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY35263A (es) Compuestos terapéuticos
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
CL2021001098A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2016001304A (es) Polimorfo de inhibidores de syk.
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
DOP2020000083A (es) Compuesto de pirimidina como inhibidor de las janocinasas
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
UY36651A (es) Compuestos antiestrogénicos
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
NI202100055A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo.
UY36123A (es) Derivados de carboxamida
MY209356A (en) A xinafoate salt of a jak inhibiting compound
CU24661B1 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
AR090959A1 (es) Analogos de hexadepsipeptidos como compuestos anticancerigenos
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende